ArticleFrontiers in medicine2026
Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with hypercalcemia: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical characteristics and identify prognostic factors in patients with newly diagnosed multiple myeloma (NDMM) who presenting with hypercalcemia. Methods: We retrospectively analyzed clinical and laboratory data from 82 NDMM patients with hypercalcemia who were admitted to the Department of Hematology at Zhongda Hospital (Southeast University) and Jiangning Hospital (Nanjing Medical University) between January 2015 and December 2024. 80 patients without hypercalcemia were randomly selected as a control group for comparison. Prognostic evaluations were based on overall survival (OS), progression-free survival (PFS), and minimal residual disease (MRD) status. Survival rates were estimated using the Kaplan-Meier method, with univariate analyses performed via the Log-rank test and multivariate analyses utilizing the Cox proportional hazards regression model. Results: The cohort comprised 82 patients (51 males, 31 females). By the end of the follow-up period, with the median follow-up time was 51 months (range, 6-128): 59 patients had died and 23 were alive. Univariate analysis revealed that cytogenetic abnormalities (detected by FISH), serum creatinine, ferritin, MRD status, and serum calcium levels significantly affected both OS and PFS. Multivariate Cox regression demonstrated that the presence of ≤ 1 FISH abnormality and MRD negativity were independent protective factors for OS. Notably, elevated serum ferritin (≥500 ng/mL), a marker previously underexplored in this context, emerged as a robust independent risk factor for both OS and PFS. Severe hypercalcemia (≥3.5 mmol/L) was also identified as an independent risk factor for both OS and PFS. For PFS, MRD negativity remained an independent protective factor, whereas ferritin ≥500 ng/mL and serum calcium ≥3.5 mmol/L were identified as independent risk factors. Conclusion: NDMM patients with hypercalcemia exhibited a substantial tumor burden, heterogeneous clinical manifestations, and a high rate of early mortality. Prompt correction of serum calcium levels, with adjustment for concurrent hypoalbuminemia, is imperative. Early detection and optimal management of hypercalcemia are essential to refining treatment strategies and improving survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.